摘要:
The present invention provides methods of using EGFL7 antagonist to modulate vascular development. Also provided herein are methods of screening for modulators of EGFL7 activity. Furthermore, methods of treatment using EGFL7 antagonists are provided.
摘要:
The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
摘要:
The present invention provides methods of using EGFL7 antagonist to modulate vascular development. Also provided herein are methods of screening for modulators of EGFL7 activity. Furthermore, methods of treatment using EGFL7 antagonists are provided.
摘要:
The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
摘要:
The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
摘要:
The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
摘要:
The invention provides methods and compositions for modulating vascularization and angiogenesis, including selective modulation of stages of multi-step vascularization and angiogenesis.
摘要:
The present invention provides novel polypeptides, antibodies, antagonists, agonists, potentiators, nucleic acid molecules, compositions and methods relating to the STOP-1 polypeptide that are useful for treating and preventing diseases and for medical diagnosis and research. The present invention also provides consensus sequences and specific sequences for antibodies that specifically bind to STOP-1 that are useful in the methods described herein.
摘要:
The present invention concerns compositions and methods for the treatment of disorders characterized by the over-expression of an LIV-1. More specifically, the compositions include DNA and amino acid sequences of an LIV-1, antibodies to an LIV-1, and methods for the treatment of a mammal susceptible to or diagnosed with cancer wherein an LIV-1 is overexpressed.